Fovista (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023 Press Release
Fovista (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023 Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Fovista is a first-in-class anti-platelet-derived growth factor (anti-PDGF) agent being developed by Ophthotech for the treatment of wAMD as a combination therapy with an anti-VEGF drug, such as Lucentis, Avastin, or Eylea. The company is currently conducting a Phase III clinical program consisting of three large trials that are investigating the efficacy of Fovista combination therapy with anti-VEGF agents in comparison with anti-VEGF monotherapy, which is the current standard of care across the 7MM. Scope - Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Fovista including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Fovista for the top country from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return. - Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. - Make more informed business decisions from insightful and in-depth analysis of Fovista performance. - Obtain sales forecast for Fovista from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan). Relevant Report Names: •
Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023 •
Optina (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023 •
DE-102 (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023 Contact Us:
Norah Trent sales@wiseguyreports.com +1 646 845 9349 / +44 208 133 9349 Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and subcategories. The Wise Guy Reports team prides itself in being the chosen source for market research reports, report customization services, and other ancillary services such as a Newsletter service and corporate service for large organizations.